Literature DB >> 28845339

Avoiding the Tragedy of the Commons in Health Care: Policy Options for Covering High-Cost Cures.

Soeren Mattke, Hangsheng Liu, Emily Hoch, Andrew W Mulcahy.   

Abstract

In this article, Mattke and his colleagues discuss the risk that strategic behavior by health insurers could unravel the market for curative therapies for chronic diseases. Because the cost of these cures is front-loaded but the benefits accrue over time, insurers might attempt to delay treatment or avoid patients who require it, in the hope that they might change insurers. The authors discuss policy options to remedy this potential free-rider problem through alignment of incentives at the patient level, coordination among payers, and government intervention. They present a framework to analyze policy options and real-world case studies. While implementing those policy options is far from easy, stakeholders need to collaborate in order to establish equitable mechanisms that fairly distribute the cost and benefits of high-cost cures.

Entities:  

Keywords:  Chronic Diseases and Conditions; Health Care Access; Health Care Costs; Health Insurance Benefit Design; Health Insurance Markets

Year:  2017        PMID: 28845339      PMCID: PMC5568155     

Source DB:  PubMed          Journal:  Rand Health Q        ISSN: 2162-8254


  14 in total

1.  Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.

Authors:  H Kirk Hammond; William F Penny; Jay H Traverse; Timothy D Henry; Matthew W Watkins; Clyde W Yancy; Ranya N Sweis; Eric D Adler; Amit N Patel; David R Murray; Robert S Ross; Valmik Bhargava; Alan Maisel; Denise D Barnard; N Chin Lai; Nancy D Dalton; Martin L Lee; Sanjiv M Narayan; Daniel G Blanchard; Mei Hua Gao
Journal:  JAMA Cardiol       Date:  2016-05-01       Impact factor: 14.676

2.  Acute heart failure syndromes: current state and framework for future research.

Authors:  Mihai Gheorghiade; Faiez Zannad; George Sopko; Liviu Klein; Ileana L Piña; Marvin A Konstam; Barry M Massie; Edmond Roland; Shari Targum; Sean P Collins; Gerasimos Filippatos; Luigi Tavazzi
Journal:  Circulation       Date:  2005-12-20       Impact factor: 29.690

3.  Option pricing: a flexible tool to disseminate shared savings contracts.

Authors:  Mark W Friedberg; Anthony M Buendia; Katherine E Lauderdale; Peter S Hussey
Journal:  Am J Manag Care       Date:  2013-08-01       Impact factor: 2.229

4.  Financing cures in the United States.

Authors:  Anirban Basu
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-12-06       Impact factor: 2.217

5.  Health plan retention and pharmacy costs of newly diagnosed patients with chronic kidney disease in a managed care population.

Authors:  Maureen Kubacki; Chureen Carter; Alan D L Herrera; Jim Wang; Janice M Lopez; Catherine T Piech
Journal:  Am Health Drug Benefits       Date:  2009-11

6.  Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.

Authors:  Stuart C Gordon; Paul J Pockros; Norah A Terrault; Robert S Hoop; Ami Buikema; David Nerenz; Fayez M Hamzeh
Journal:  Hepatology       Date:  2012-10-09       Impact factor: 17.425

Review 7.  Therapeutic targeting of tumor suppressor genes.

Authors:  Luc G T Morris; Timothy A Chan
Journal:  Cancer       Date:  2014-12-29       Impact factor: 6.860

8.  Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Authors:  Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

9.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

10.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

View more
  1 in total

1.  The economics of alternative payment models for pharmaceuticals.

Authors:  Jakub P Hlávka; Jeffrey C Yu; Dana P Goldman; Darius N Lakdawalla
Journal:  Eur J Health Econ       Date:  2021-03-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.